Table 2

Characteristics of patients included in the meta-analysis

TrialAge
(years)
Women
(%)
KL grade
3/4 (%)
Level
of pain
BMI
(kg/m2)
Duration of
symptoms
(years)
No randomised/
analysed (n)
experimental
control
Time of assessment
Shichikawa et al25NA8324.563.5 (0–100)NANA114/96114/10212 weeks
Puhl et al266164NA52.7 (mm, VAS)26.9NA102/95107/1009 weeks
Altman et al27635538.510.1 (WOMAC)29.96173/172174/17413 weeks
Petrella and Petrella29634525.620.3 (WOMAC)30.4NA53/5353/5340 months
Lundsgaard et al30695536.854.5 (mm, VAS)29.4884/8184/8012 weeks
Altman et al28626360.055.1 (mm, VAS)32.7NA293/291295/29512 weeks
Chevalier et al32637154.42.27 (WOMAC)29.36124/124129/12912 weeks
Navarro-Sarabia et al31648427.470.4 (mm, VAS)28.68153/149153/15224 weeks
  • BMI, body mass index; NA, not applicable; VAS, visual analog scale; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.